Quality Concerns Hits APAC
BioSpectrum Asia|BioSpectrum Asia August 2023
India is not alone in witnessing adverse events of various drugs. Several countries such as Japan, China, Malaysia, Indonesia and many more have experienced challenges such as contamination, efficacy, and safety issues (with serious adverse events), resulting in drug recalls in the past few years. As with any incident, an in-depth look will bring forth the root of the problem. Let's explore.
- Sanjiv Das
Quality Concerns Hits APAC

In February 2023, the Drug Regulatory Authority of Pakistan (DRAP) recalled seven products manufactured by Islamabad-based Davis Pharmaceutical Laboratories in Pakistan because of the discovery of ethylene glycol at unacceptable levels.

The likely cause for contamination for KOF Relief Syrup and six other products were due to the using of the same sources of glycerin and propylene glycol. Four of the products, including KOF Relief Syrup, were manufactured for export.

DRAP was expected to take action against the syrup manufacturer, potentially by cancelling its production license and by subsequent arrests.

In June 2023, Pakistan published changes to its drug pricing policy. The revisions cover the definition of the term essential drugs and biologicals, which officials have expanded to cover all strengths of a medicine.

In March 2023, Malaysia’s Drug Control Authority (DCA) also recalled pholcodine-containing cough and cold medicines, citing the risk of anaphylaxis in surgery.

Australia’s Therapeutic Goods Administration (TGA) published a safety alert in February 2023 about Abbott’s FreeStyle LibreLink Android app. The alert describes a fault that could prevent users from receiving information they need to manage their blood sugar levels. According to TGA, users may experience extended periods of signal loss and during this time they won’t receive high or low glucose alarms.

Abbott has taken steps and has released the latest version of the FreeStyle LibreLink app (version 2.8.4), and has recommended Android 13 OS users of the FreeStyle Libre 2 to update their app to this latest version. Abbott has also released the latest version of the FreeStyle Libre 3 app (version 3.4.2).

この蚘事は BioSpectrum Asia の BioSpectrum Asia August 2023 版に掲茉されおいたす。

7 日間の Magzter GOLD 無料トラむアルを開始しお、䜕千もの厳遞されたプレミアム ストヌリヌ、8,500 以䞊の雑誌や新聞にアクセスしおください。

この蚘事は BioSpectrum Asia の BioSpectrum Asia August 2023 版に掲茉されおいたす。

7 日間の Magzter GOLD 無料トラむアルを開始しお、䜕千もの厳遞されたプレミアム ストヌリヌ、8,500 以䞊の雑誌や新聞にアクセスしおください。

BIOSPECTRUM ASIAのその他の蚘事すべお衚瀺
New South Wales government injects $5M for critical research to address Silicosis crisis
BioSpectrum Asia

New South Wales government injects $5M for critical research to address Silicosis crisis

The New South Wales (NSW) government in Australia has committed $5 million in critical funding for silicosis research and a patient support programme for individuals and their families navigating the health risks associated with exposure to silica dust.

time-read
1 min  |
BioSpectrum Asia May2024
Singapore approves new asthma indication for GSK's Trelegy Ellipta
BioSpectrum Asia

Singapore approves new asthma indication for GSK's Trelegy Ellipta

GSK Singapore has announced that the Health Sciences Authority (HSA) has approved a new indication and a new strength for Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol 'FF/UMEC/VI') for the maintenance treatment of asthma in patients aged 18 years and older who are not adequately controlled with a combination of a long-acting beta2-agonist (LABA) and an inhaled corticosteroid (ICS).

time-read
1 min  |
BioSpectrum Asia May2024
What's APAC's Recipe of Success in CLINICAL TRIALS MARKET?
BioSpectrum Asia

What's APAC's Recipe of Success in CLINICAL TRIALS MARKET?

Asia-Pacific APAC) is emerging as one of the most promising and resilient markets for clinical trials. According to a report by Clinical Trials Arena, between 2017 and 2022, the region posted growth in clinical trials of around 10 per cent, outstripping growth in other major regions including the US, Europe and the rest of the world RoW). Asia’s growth far exceeded the overall average figure of 5.3 per cent per year. As of 2023, the number of trials reached 14,346 in APAC. Let's delve into the thriving clinical research landscape in the region and explore the trends driving its growth.

time-read
10+ 分  |
BioSpectrum Asia May2024
From Haematologic to Autoimmune DiseaseThe CAR-T Therapy Second Revolution
BioSpectrum Asia

From Haematologic to Autoimmune DiseaseThe CAR-T Therapy Second Revolution

Cell and gene therapies have revolutionised the field of medicine, offering new treatment options for patients with various diseases that, by type of disease or severity, were considered untreatable until a few years ago. Rapid technological advancements in genetic and biological engineering and improvements in the quality and standardisation of the manufacturing process are fostering a marked increase in clinical development of these advanced therapies, generally named cell and gene therapies CGT), and they are expected to receive more approvals in the near future.

time-read
5 分  |
BioSpectrum Asia May2024
"Biotech startups still need support in terms of talent, and resources to bring their innovations to market"
BioSpectrum Asia

"Biotech startups still need support in terms of talent, and resources to bring their innovations to market"

Raymond Chow has recently stepped in as the Vice President, Asia Pacific at USheadquartered Cytiva, a global provider of technologies and services for biological therapies, formerly known as GE Healthcare Life Sciences.

time-read
5 分  |
BioSpectrum Asia May2024
"We are exploring opportunities to collaborate with startups and incubators"
BioSpectrum Asia

"We are exploring opportunities to collaborate with startups and incubators"

Agilent Technologies, a global leader in analytical and clinical laboratory technologies, has named Padraig McDonnell CEO-elect and Chief Operating Officer (COO), succeeding current President and CEO Mike McMullen.

time-read
5 分  |
BioSpectrum Asia May2024
"Australia offers a simple, supportive and robust regulatory process to initiate human trials efficiently"
BioSpectrum Asia

"Australia offers a simple, supportive and robust regulatory process to initiate human trials efficiently"

US-based Uvax Bio, LLC, a spin-off vaccine company from Scripps Research, employs proprietary 1c-SApNP platform technology invented by Dr Jiang Zhu of Scripps Research to develop and commercialise prophylactic vaccines for challenging infectious diseases.

time-read
2 分  |
BioSpectrum Asia May2024
"Regulatory encouragement of advanced tech, including AI will accelerate clinical trials in APAC"
BioSpectrum Asia

"Regulatory encouragement of advanced tech, including AI will accelerate clinical trials in APAC"

Lokavant Holdings, a US-based clinical trial intelligence technology company provides clinical trial intelligence that enables study teams to make data-driven decisions, as well as risk-based quality management and monitoring services to pharmaceutical companies and contract research organisations (CROs).

time-read
2 分  |
BioSpectrum Asia May2024
What Are the Main Challenges of Modern Clinical Trials?
BioSpectrum Asia

What Are the Main Challenges of Modern Clinical Trials?

With a cumulative total of almost 478,000 globally registered trials from the year 2000 to 2023, and growing at around 10 per cent a year in the last five years, the pharmaceutical industry continues to invest in clinical trials as the gold-standard test of therapeutic safety and efficacy. In addition, as the world’s economies and populations move in new directions, the share of non-US trials has reached 54 per cent, a trend that is likely to continue, driven by demographics and epidemiology. As the pace accelerates, trial managers and clinicians face a significant challenge: the explosive growth of data volumes. To succeed in the future, clinical trials need to increase efficiency and better utilise clinical trial data to support informed clinical and operational decision-making.

time-read
3 分  |
BioSpectrum Asia May2024
How APAC Has Turned into Clinical Trial Behemoth
BioSpectrum Asia

How APAC Has Turned into Clinical Trial Behemoth

From being a consistent participant in clinical trial conduct worldwide, the APAC has emerged as a major power. A number of causes, including the region's thriving drug development innovation and the ongoing presence of international pharmaceutical corporations conducting multiregional studies, are driving this growth.

time-read
3 分  |
BioSpectrum Asia May2024